SAFETY: Stabilization Points to Third Hospital Line Assessment oF the Impact of the usE of Infrascanner Model 2500 to Provide Decision Support for Diagnosis/Screening of Traumatic Brain InjurY in Ukraine

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

600 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-01-17

Study Completion Date

2026-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Infrascanner model 2500 is a handheld, noninvasive device that is FDA-cleared to detect traumatic intracranial hematomas. FDA clearance K200203 was issued in 2020, K211617 added pediatric age group to the IFU in 2022, and K241389 approved higher laser power use to address dark skinned patients in 2024. This non randomized observational study aims to evaluate the utility of this device by evaluating its ability to provide decision support information to optimize care for patients with suspected traumatic intracranial hematomas. It is important to note that the intended use of the device is in accordance with its FDA approved indication. The intent is to generate actionable knowledge that along with standard clinical signs, facilitates the early detection of intracranial hemorrhage (ICH) in patients with suspected traumatic brain injury (TBI) in a combat setting. The ultimate goal is to modify and optimize international protocols for inexpensive, bedside, portable, and noninvasive detection of traumatic ICH in conflict zones across the globe.

This multicenter, prospective, observational, implementation science study will evaluate the field utility of the Infrascanner Model 2500 in an active combat setting using a pragmatic, sequential research design consisting of two phases-baseline phase and device phase. Using the current Ukrainian medical care system, patients with suspected TBIs will be monitored, and their outcomes will be tracked using standard-of-care practices (baseline phase). After the baseline data collection period is complete, an amendment to the protocol will be submitted to initiate the device phase. After training and upon approval, the Infrascanner device will be deployed to the facilities described above to provide health care providers with additional decision support, and the impact of its use will be compared to the baseline data. The outcome of interest is the time from admission at each enrollment study location to a definitive CT scan diagnosis of ICH. The investigators hypothesize that the use of the device will provide decision support to health care providers, decrease the time to traumatic ICH detection, thus enabling more expedient care.

This prospective study will include all patients with suspected combat-related head trauma identified by clinical signs of TBI, such as decreased GCS score, abnormal pupil exam, and/or asymmetrical motor exam, on admission to the clinical enrollment site (mobile hospital or regional clinical hospital) regardless of the presence of pharmacologic sedation. At the Vinnytsia hospital (Role 4), combat polytrauma preoperative patients will also be screened. Exclusion criteria include evidence of extensive scalp injury, including lacerations, avulsions, or abrasions that prevent proper placement of the Infrascanner device on a subject's head or prevent placement of the device in the specified locations.

During the baseline phase (Figure 1), 100 patients will be enrolled at stabilization points and the mobile/first-line hospital, 100 will be enrolled at the second-line hospital, and 100 will be enrolled at the third-line hospital. Thus, from a total of 300 subjects, baseline data on the time from admission at each enrollment study location to a definitive CT scan diagnosis of ICH and treatment and early outcomes will be collected.

Once the baseline phase is complete and the amendment for the device phase is approved, it will be initiated. During this device phase, the Infrascanner will be deployed to stabilization points and the three levels of care (mobile hospitals and regional clinical hospitals). Data collection will continue until 100 patients are enrolled in the device phase for the three levels of care. All data collection at the baseline and device phases will occur at the same locations, and the data elements will be identical, except for Infrascanner data collected during the device phase.

By comparing data from the baseline and device phase, the investigators will assess the utility of the device to provide decision support information to providers and potentially reduce time to definitive diagnosis by CT scan and thus treatment, as well as the association between Infrascanner use and early patient outcomes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Detecting Traumatic Intracranial Hemorrhage With the InfraScanner 2500™ in Uganda

NCT06491173

Head Trauma Crushing Skull Injury Head Injury +13 more

COMPLETED NA

Assessment of InfraScanner 2000™ in Detecting Subdural and Epidural Hematomas

NCT03353246

Head Trauma Craniocerebral Injuries Crushing Skull Injury +13 more

COMPLETED NA

Assessment of InfraScanner 2000™ in Detecting Subdural and Epidural Hematomas

NCT04505293

Head Trauma Craniocerebral Injuries Crushing Skull Injury +13 more

COMPLETED NA

Confounding Factors in the Detection of Intracranial Hemorrhage With the Infrascanner

NCT02809651

Ischemic Stroke Brain Tumor Brain Surgery +3 more

COMPLETED NA

A Multi-Center Study of Near-Infrared Spectroscopy (NIRS) for Hematoma Detection

NCT00576147

TBI (Traumatic Brain Injury)

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Traumatic Brain Hemorrhage

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Baseline Phase

Patients with suspected combat-related head trauma who are admitted to the participating hospitals will be eligible for enrollment in this trial. These patients will receive the current standard of care.

No interventions assigned to this group

Device Phase

Patients with suspected combat-related head trauma who are admitted to the participating hospitals will be eligible for enrollment in this trial. These patients will receive the current standard of care and the Infrascanner model 2500 will be added to the diagnosis and clinical decision.

Handheld brain hematoma detector

Intervention Type DIAGNOSTIC_TEST

Near Infrared based handheld traumatic brain hematoma detector

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Handheld brain hematoma detector

Near Infrared based handheld traumatic brain hematoma detector

Intervention Type DIAGNOSTIC_TEST

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Infrascanner Model 2500

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with suspected combat-related head trauma identified by clinical signs of TBI on admission to the clinical enrollment site
* Clinical signs of TBI:

* Decreased GCS score
* Abnormal pupil exam
* Asymmetrical motor exam

Exclusion Criteria

* Evidence of extensive scalp injury that prevent proper placement of the Infrascanner device on a subject's head or prevent placement of the device in the specified locations.
* Extensive scalp injury includes lacerations, avulsions, or abrasions

Eligible Sex

ALL

Accepts Healthy Volunteers

No